Detalles de la búsqueda
1.
Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil.
BMC Neurol
; 22(1): 301, 2022 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35978300
2.
Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease.
Alzheimers Dement
; 13(3): 312-321, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28063281
3.
Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Value Health
; 18(6): 925-38, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26409621
4.
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study.
Clinicoecon Outcomes Res
; 16: 55-67, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348373
5.
Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons.
Ther Adv Neurol Disord
; 17: 17562864241239453, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38525490
6.
Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
J Med Econ
; 26(1): 11-18, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36472139
7.
Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231201422, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37780483
8.
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
J Comp Eff Res
; 12(7): e230016, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37265062
9.
Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS.
Patient
; 16(4): 345-357, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017920
10.
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
J Comp Eff Res
; 12(9): e220175, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37606897
11.
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Mult Scler J Exp Transl Clin
; 9(1): 20552173231153557, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36816812
12.
How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
J Cent Nerv Syst Dis
; 14: 11795735221115912, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958354
13.
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients.
Appl Health Econ Health Policy
; 20(5): 731-742, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35585305
14.
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.
Mult Scler J Exp Transl Clin
; 8(1): 20552173221085741, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35371535
15.
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
Pharmacoecon Open
; 6(6): 859-870, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36107307
16.
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Mult Scler Relat Disord
; 66: 104031, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35841716
17.
How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.
Neurol Ther
; 10(2): 557-583, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34279847
18.
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
Curr Med Res Opin
; 37(6): 995-1004, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33733976
19.
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
Pharmacoeconomics
; 39(5): 563-577, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33791945
20.
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Curr Med Res Opin
; 37(11): 1933-1944, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34384311